VOLUME 16 | NUMBER 10 | OCTOBER 2010 nature medicine a r t i c l e s Pneumonia can be a devastating and immediate cause of death among all age groups, and it is second only to childbirth for hospital admission 1 . Thus, it remains a major cause of morbidity and contributes substantially to healthcare costs in both the community and among hospitalized individuals. The pathobiology of bacterial pneumonia after infection with highly virulent pathogens (Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae and Escherichia coli) typically involves neutrophilic lung infiltration and a robust host immune response, leading to severe ventilatory abnormalities. Numerous microbial virulence and host factors participate in the progression of pulmonary injury 2 . Yet despite decades of intensive study, there has been a lack of fundamentally new biological mechanisms with regard to the pathobiology of bacterial pneumonia. Consequently, there has been an overreliance on the use of broadspectrum antibiotics in severe infection, causing the emergence of multidrug-resistant bacterial strains.
apical epithelial membranes and is present in various human tissues 8 . The observation that people with PFIC1 are prone to respiratory infection, coupled with the ability of ATP8b1 to transport phospholipids across cellular membranes, led us to hypothesize that ATP8b1 is a cardiolipin import protein. To test this hypothesis, we analyzed Atp8b1-defective mice that harbor a naturally occurring ATP8b1 mutation (G308V) observed in individuals with severe PFIC1.
In this study, we discovered that cardiolipin concentrations are elevated in the lung fluid of individuals with pneumonia and that it is a highly potent surfactant inhibitor that disrupts lung structure and function. The abundance of cardiolipin in lung fluid is regulated by Atp8b1, which effectively binds and internalizes cardiolipin in lung epithelia via domain-specific interactions. Atp8b1-mutant mice have elevated cardiolipin concentrations in lung fluid and are prone to bacterial-induced lung injury. These results provide a new conceptual model for bacterial pneumonia, where Atp8b1 serves as a molecular transporter that removes an injurious bioactive lipid from distal airways to preserve pulmonary function.
RESULTS

Cardiolipin is elevated in pneumonitis
We quantified cardiolipin in tracheal aspirates from critically ill subjects with nonpulmonary illnesses (n = 5), clinically diagnosed pneumonia (n = 17) or congestive heart failure (CHF) (n = 6) (Supplementary Table 1 ). The control subjects with nonpulmonary illnesses included some requiring mechanical ventilation for liver failure, and some with hemolysis elevated liver enzymes low platelets (HELLP) syndrome, Guillain-Barré syndrome, renal failure or gastrointestinal tract bleeding. Subjects with pneumonia were identified as having new or changing radiographic pulmonary infiltrates, increasing sputum quantity or change in sputum character, and clinical features such as fever, elevated white blood cell count and hypoxemia, without dependence upon sputum culture results or distinction between community or hospital acquisition (data not shown). No bacterial growth was detected in 39% (7/17) of tracheal aspirates from subjects with pneumonia, whereas S. pneumoniae grew from four subjects, Pseudomonas aeruginosa and S. aureus grew from three subjects each and H. influenzae grew from one subject. Ninety percent (26/28) of all subjects were on broad-spectrum antibiotics on the day of tracheal aspirate collection (Supplementary Table 1 ). Subjects with pneumonia had significantly higher amounts of cardiolipin (median = 12.9 mol%) in tracheal aspirates compared to subjects with nonpulmonary diagnoses (~9.7 fold) or CHF (approximately sixfold, Kruskal-Wallis P = 0.0007, Fig. 1a) . Notably, cardiolipin abundance did not correlate with culture status, bacterial pathogen, duration of mechanical ventilation, gender or age (Supplementary Fig. 1 ).
We also infected mice with strains of H. influenzae or E. coli that cause pneumonia 10, 11 . Bronchoalveolar lavage (BAL) fluid from infected mice had greater amounts of cardiolipin than BAL isolated from uninfected mice (Fig. 1b) . To assess whether the high cardiolipin levels were due to reduced cellular uptake, we cultured primary mouse type II lung epithelia with [ 3 H]cardiolipin. Infection of cells with H. influenzae or E. coli resulted in significantly less cellular uptake of [ 3 H]cardiolipin (Fig. 1c) . Thus, cardiolipin concentrations are increased in lung fluid of both humans and mice with pneumonitis, and this may be the result of decreased epithelial uptake of the phospholipid.
Because cardiolipin is a constituent of bacterial membranes, it is plausible that its release into lung fluid during pneumonia represents infections having very high bacterial burdens. Alternatively, elevated cardiolipin in lung fluid could originate from dying host cells, as it is exclusively present within the inner mitochondrial membrane and is released during intrinsic mitochondria-dependent apoptosis. Because the molecular signatures of cardiolipin species differ between mammalian cells and bacterial membranes, we examined the source of cardiolipin in humans with pneumonia ( Supplementary Fig. 2a ) and mice infected with E. coli (Supplementary Fig. 2b ). Electrospray ionization mass spectrometry spectra of these cardiolipins obtained from human and mouse samples show that cardiolipin originates from mammalian cells. Thus, we found mitochondria-specific mammalian species of cardiolipin, and not bacterial types, in lung fluid samples.
Cardiolipin impairs lung structure, function and cell viability We measured surface tension-lowering activity of lipid vesicles in vitro. The lipid vesicles were generated by incorporating phospholipids (cardiolipin, lysophosphatidylcholine and phosphatidylserine) into Infasurf, a commercial apoprotein-containing surfactant that lowers surface tension (Fig. 2a) . We also extracted lipids from Infasurf by organic solvent extraction to generate Infasurf protein-deficient preparations that we reconstituted with phospholipids for testing (Fig. 2b) . Unlike phosphatidylserine, cardiolipin at high concentrations (>3 mol%) resulted in increased surface tension (Fig. 2a) . Cardiolipin impaired the surface tension-lowering activity of Infasurf to a greater extent than did lysophosphatidylcholine, a positive control (Fig. 2a) 12 . These adverse effects of cardiolipin were more pronounced when testing Infasurf extracts devoid of surfactant-associated apoproteins (Fig. 2b) . Mice given intratracheal (i.t.) cardiolipin had significantly lower lung compliance and higher elastance and resistance compared to controls (Fig. 2c-f) . Cardiolipin administration also increased BAL protein concentration (Supplementary Fig. 3a) , differentially altered surfactant protein expression (Supplementary Fig. 3b ) and reduced γ-interferon and interleukin-2 (IL-2) protein levels and increased , quasistatic pressurevolume curves (d), elastance (e) and resistance (f) in mice (three to five per group) that were anesthetized, paralyzed and mechanically ventilated with positive-end expiratory pressure of 3, as determined with a FlexiVent system after i.t. application of phosphatidylglycerol (PG) or cardiolipin (x axis in c, e and f represents amount of lipid). Significance was determined by one-way ANOVA. *P < 0.05, **P < 0.01 and ***P < 0.001 versus control. Fig. 3c,d ), but it did not affect the distribution of various inflammatory cells ( Supplementary  Fig. 3e ) in BAL. Thus, cardiolipin in lung fluid adversely affects lung mechanics by greatly impairing surfactant activity. It also modulates expression of cytokine networks that could affect lung function.
IL-10 protein levels (Supplementary
We next addressed whether the adverse functional effects of cardiolipin led to altered lung structure. Mice were subjected to live imaging of lungs by microcomputed tomography (microCT) scanning (Supplementary Methods). Compared to mice given diluent, mice given cardiolipin (50 nmol) had more prominent markings in parenchyma with scattered patchy areas of alveolar consolidation (Fig. 3a) . These abnormalities were more severe after high doses of cardiolipin. Histological analysis identified areas of alveolar infiltration and the appearance of foamy cells within alveoli (Fig. 3a) . High-dose cardiolipin produced edema and disruption of alveolar lining cells ( Fig. 3a-c ) that contributed to fatality of mice within 2-3 h. Cardiolipin activated the apoptotic program in cells and in tissue ( Fig. 3d ) and decreased cell viability (Fig. 3e, 
f).
Atp8b1 is an alveolar epithelial cardiolipin importer Because cardiolipin is internalized by alveolar cells (Fig. 1c) , we hypothesized that cells would express an import protein that regulates cardiolipin abundance in lung fluid. ATP8b1 was a candidate protein, as it internalizes phospholipids and because humans with ATP8b1 defects are prone to pneumonia 9 . Mouse type II cells had high level expression of Atp8b1 compared to macrophages or fibroblasts ( Supplementary Fig. 4a ), and this expression was upregulated by phospholipids ( Supplementary Fig. 4b ) and localized predominately to the cell surface ( Supplementary Fig. 4c ). Cells expressing lentivirus-encoded Atp8b1 had higher levels of mRNA and protein expression, coupled with a robust increase in the uptake of fluorescent nitrobenzoxadiazole (NBD)-labeled cardiolipin or phosphatidylserine (positive control) compared to untransduced cells (Fig. 4a,b and Supplementary Fig. 4d ). Atp8b1-overexpressing cells had greater fluorescence on both the cell surface and inside the cells, indicating that the NBD-labeled cardiolipin was located on the plasma membrane and within the cytoplasm. Although Atp8b1 internalized cardiolipin, it did not enhance GFP-labeled E. coli uptake (Supplementary Fig. 4e) . Notably, H. influenzae triggers Atp8b1 degradation and ubiquitination (Supplementary Fig. 5 ). Other related ATP-driven pumps, Atp8a1 and Atp11a, did not transport cardiolipin (Supplementary Fig. 6 ).
We also gave mice adenovirus (Ad5) encoding Atp8b1 or empty adenovirus intratracheally before E. coli infection to assess lung function. Mice infected with E. coli at 1 × 10 6 colony-forming units (CFU) per mouse had cleared the pathogens by 48 h of analysis (data not shown). These mice showed decreased percentages of BAL macrophages with a neutrophilic infiltrate typical of pneumonia, a profile not affected 72 h after Ad5-Atp8b1 gene transfer (Supplementary Fig. 7a ). Mice given Ad5 alone or Ad5 encoding Atp8b1 tended to have high BAL protein concentrations associated with the release of proinflammatory cytokines after bacterial infection (Supplementary Fig. 7b,c) . Atp8b1 gene delivery before E. coli infection also lowered the expression of collectins, surfactant protein A (SP-A) and SP-D but did not affect the expression of SP-B, the latter being essential for surfactant activity ( Supplementary  Fig. 7d) . Notably, Atp8b1 gene delivery effectively increased Atp8b1 levels, lowered cardiolipin levels and reversed E. coli-induced impairment of lung mechanics (Fig. 4c,d and Supplementary Fig. 7e ) compared to infected mice given empty Ad5. Atp8b1 gene transfer did not reduce apoptosis after bacterial infection (Fig. 4e) . Thus, the primary mechanism for the beneficial effects of increased Atp8b1 expression is reduced cardiolipin availability, which preserves surfactant function and improves lung mechanics. These effects were sufficient to result in increased survival of E. coli-infected mice (Fig. 4f) .
We performed additional loss-of-function studies with Atp8b1-specific siRNA and Atp8b1-mutant mice that harbor a single amino acid substitution (G308V) resulting in a defect in cellular import of phosphatidylserine 13, 14 . Atp8b1-targeting siRNA produced a significant decrease in cardiolipin uptake and specifically reduced the amount of immunoreactive Atp8b1 compared to scrambled RNA (Fig. 5a) . Restriction digests of genomic DNA revealed that the mutant mice lacked 500-bp and 300-bp digest fragments (Fig. 5b ). We detected low-level Atp8b1 protein expression in mutant mouse liver and lung compared to wild-type mouse tissues (Fig. 5c) . Atp8b1-mutant mice had significantly higher BAL cardiolipin concentrations as compared to wild-type littermates a r t i c l e s nature medicine VOLUME 16 | NUMBER 10 | OCTOBER 2010 1 1 2 3
( Fig. 5d) . Consistent with Atp8b1's inability to alter uptake of bacteria, bacterial loads did not differ between Atp8b1-mutant and wild-type mice (Supplementary Fig. 8a ). Both Atp8b1-defective and wild-type littermates showed no differences in BAL protein content (Supplementary Fig. 8b ), wet-dry lung weight ratios ( Supplementary  Fig. 8c ) or cellular inflammation (Supplementary Fig. 8d ) after E. coli infection. Of note, ATP8b1-defective mice had a blunted cytokine response to T helper type 1 cytokines (interferon (IFN)-γ, tumor necrosis factor (TNF)-α and IL-1β) compared to wild-type littermates after E. coli infection (Supplementary Fig. 9a,b) which may be secondary to increased expression of SP-A and SP-D ( Supplementary  Fig. 9c ) 15, 16 . Primary type II cells isolated from Atp8b1-mutant mice had significantly (P < 0.05) reduced NBD-cardiolipin uptake compared to cells isolated from wild-type littermates (Fig. 5e ). Mutant mice also had impaired biophysical properties compared to wild-type mice, particularly after E. coli infection (Fig. 5f,g and Supplementary Fig. 9d ). Although lung cells from mutant mice were more prone to apoptosis (Fig. 5h) , there was no significant difference in mortality between Atp8b1-mutant and wild-type mice with infection ( Fig. 5i) . Collectively, these studies strongly suggest that Atp8b1 is a bona fide alveolar epithelial cardiolipin import pump.
Cardiolipin binding domain peptide blocks cardiolipin effects
We mapped the Atp8b1 cardiolipin binding domain (CBD). We synthesized deletion mutants by in vitro translation ( Supplementary  Fig. 10a,b) and then reacted them with 15 lipids prespotted onto hydrophobic lipid strips (Supplementary Fig. 10c ). With this system, we found that full-length Atp8b1 and specific mutants bound cardiolipin and also sulfatide (sulfated galactosylceramides) ( Supplementary  Fig. 10c ). C-terminal truncation mutants containing only the first 810 or 771 residues did not bind cardiolipin, suggesting that the CBD resides between residues 810 and 850 within Atp8b1. We confirmed this by testing a fragment (residues 771-850) that was sufficient for cardiolipin binding, indicating that a CBD resides within the Atp8b1 carboxy terminus (Supplementary Fig. 10c ).
We expressed and purified GST fused to the putative CBD from cells. Mouse lung epithelial (MLE) cells cultured with GST-CBD peptide showed an 83% decrease in [ 3 H]cardiolipin uptake compared to culture with GST peptide alone (Fig. 6a) . Mice infected or not with E. coli and given intratracheal CBD peptide had a trend toward increased proportion of macrophages and modestly reduced protein content and neutrophils in BAL as compared to mice given vehicle ( Supplementary Fig. 11a,b) . Notably, CBD peptide profoundly lowered TNF-α and IL-1β protein levels and significantly (P < 0.05) reduced granulocyte-macrophage colony-stimulating factor protein amounts in BAL after bacterial infection ( Fig. 6 and Supplementary  Fig. 11c ). Cardiolipin also inhibited key cell survival pathways, an effect blocked by CBD peptide (Supplementary Fig. 12 ). CBD peptide did not alter surfactant apoprotein content nor the degree of lung cell apoptosis ( Supplementary Fig. 13a,c) . Infected mice given vehicle had impaired lung mechanics, effects that were reversed after CBD peptide administration (Fig. 6b-d and Supplementary  Fig. 13b ). These beneficial effects of CBD peptide on pulmonary homeostasis led to significantly improved survival in mice (Fig. 6f) . Thus, the CBD within Atp8b1 is functional with regard to substrate binding, and this peptide exerts biological effects in concert with its activity in antagonizing actions of cardiolipin in vivo.
DISCUSSION
Pneumonia remains a major public health challenge and a leading cause of intensive care unit admission. Antimicrobial agents are the cornerstone of therapy for bacterial pneumonia, but few nonantibiotic therapies have emerged that affect the outcomes of patients with severe infection. The data here provide a new conceptual model involving cardiolipin, imported by ATP8b1, that contributes to the pathobiology of pneumonia. We show that cardiolipin concentrations in pulmonary fluid are markedly elevated both in humans with pneumonia and in mice infected with bacterial pathogens. Cardiolipin potently impairs lung mechanics by antagonizing surfactant function, leading to high surface-tension pulmonary edema 17, 18 . We also observed that cardiolipin disrupts pulmonary architecture and reduces epithelial cell viability. Our finding that the adverse effects of cardiolipin are antagonized by cardiolipin-binding peptide suggest that future studies might entail the use of small-molecule modifiers that regulate cardiolipin availability as new nonantibiotic treatment strategies for patients with pneumonia.
Cardiolipin, an apoptotic cell surface marker, could be released in lung fluid in pneumonia from either dying lung cells or from bacterial membranes. The cardiolipin content in some bacterial envelopes, such as that of E. coli, is very high, but it is undetectable in H. influenzae membranes 6, 19 . Yet, as shown here, both pathogens reduced cardiolipin uptake and increased cardiolipin lung concentrations, suggesting other mechanisms for its origin. Early in programmed cell death, cardiolipin transmigrates to the outer mitochondrial membrane 20 and can also reach the outer leaflet of the cell's plasma membrane 21 , where it may be readily integrated into surfactant. Although our analysis identified that cardiolipin originates from mammalian cells, the results do not totally exclude a bacterial origin, as amounts of bacterial cardiolipin in fluid could be transient, or prokaryotic organisms might use host cell mitochondrial cardiolipin that is incorporated into bacterial membranes.
We show that cardiolipin is profoundly effective in inhibiting surfactant activity; it was twice as potent as lysophosphatidylcholine, a gold standard reference 22 . Optimal surfactant activity depends on tight molecular packing of the major surfactant phospholipid, dipalmitoylphosphatidylcholine (DPPC), within a film at the air-surface interface. Cardiolipin's ability to block surface tension lowering by DPPC would be predicted because of its bulky molecular structure, which would impede DPPC packing. It is difficult to equate cardiolipin concentrations in human tracheal aspirates (Fig. 1a) with pathophysiologic amounts of cardiolipin incorporated into the DPPC film in human BAL fluid. This is because of considerable issues of recovery and sample dilution and tight binding of cardiolipin with mitochondrial proteins, hindering its extraction 23 . However, we observed inhibitory actions of cardiolipin even at very low concentrations (~2 mol%) when we used cardiolipin liposomes devoid of surfactant apoproteins. Thus, surfactant proteins may protect against cardiolipin inhibition, and adverse cardiolipin effects may be more pronounced when surfactant proteins are depleted 24 . When we added cardiolipin to liposomes with apoproteins, surface tension was markedly elevated. In this case, higher concentrations of cardiolipin (at 5-20 mol%), as seen in people with pneumonia, are needed to impair surface activity. The in vitro data suggest that cardiolipin concentrations that impair surface activity are within the pathophysiological range. These human observations need to be confirmed in larger studies adjusted for possible confounding factors (smoking status, illness severity, lung compliance and comorbidities), as the current results in tracheal aspirates are associative and lack measures such as cell counts and a r t i c l e s proteins and were not adjusted for dilution. The use of bronchoscopy with BAL may further strengthen these associations by improving the accuracy of pneumonia diagnosis and adjusting for inflammatory markers. Subgroup analyses (for example, alveolar hemorrhage and stages of acute lung injury) are also essential in understanding these associations. Serial measurements during mechanical ventilation may better link tracheal colonization and resolving inflammation with cardiolipin content in tracheal aspirates.
Typically, very low cardiolipin concentrations are seen in human lavage fluid, suggesting that alveolar cells harbor active lipid transport mechanisms 25, 26 . We have the following evidence in support of Atp8b1 as an authentic cardiolipin import protein: Atp8b1 binds cardiolipin within a highly charged inter-transmembrane domain loop, in vivo administration of a peptide containing this putative CBD signature or Ad5-Atp8b1 gene transfer lowers cardiolipin levels, coupled with reduced lung injury severity, and Atp8b1-defective mice have increased cardiolipin levels and are vulnerable to bacterial-induced lung injury. The data might suggest that cardiolipin released during pulmonary infection exceeds the substrate binding capacity of Atp8b1. In such a scenario, bacteria could degrade Atp8b1 protein ( Supplementary Fig. 5 ), mask the cardiolipin-binding pocket by inducing Atp8b1 conformational changes or reduce pump catalytic function. Presumably, redundant mechanisms for cardiolipin import are insufficient, as ATP8b1-mutant mice showed sensitivity to pulmonary sepsis.
To our knowledge, these studies are the first demonstrating cellular uptake of cardiolipin via protein binding. We mapped the ATP8b1 CBD to a 40-residue motif within a predicted intertransmembrane loop 27, 28 . This loop contains several regulatory elements, including a D554N missense mutation seen in individuals with PFIC1 (ref. 27 ). As individuals with PFIC1 have a higher incidence of respiratory symptoms, there may be additional polymorphisms within the CBD that predispose affected individuals to infection. Administration of CBD peptide in mice substantially lessened pulmonary impairment after infection, suggesting that the molecular interactions between the ATP8b1 motif and cardiolipin are preserved in vivo. Manipulation of cardiolipin seems to modulate the inflammatory response and cell survival pathways, effects that are mitigated by CBD peptide. Thus, alveolar cardiolipin and the CBD peptide seem to exert immunomodulatory actions that could affect resolution of pulmonary injury. These results may eventually serve as a springboard to generate drug therapies to sequester or enhance clearance of injurious cardiolipin in pneumonia.
METhODS
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